ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Targeted Drugs for Multiple Myeloma Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-0V6257
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Targeted Drugs for Multiple Myeloma Market Insights and Forecast to 2028
BUY CHAPTERS

Global Targeted Drugs for Multiple Myeloma Market Research Report 2025

Code: QYRE-Auto-0V6257
Report
September 2025
Pages:113
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Celgene
Exova
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla Ltd
Glenmark Pharmaceuticals
Dr. Reddy’s Laboratories
Qilu Pharmaceutical
Chia Tai Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J & J
Takeda
Amgen Inc
Bristol–Myers Squibb
AbbVie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering Plough
Glaxo
Chiron
J & J

Targeted Drugs for Multiple Myeloma Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Targeted Drugs for Multiple Myeloma Market

Targeted Drugs for Multiple Myeloma Market

The global market for Targeted Drugs for Multiple Myeloma was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Multiple Myeloma.
The Targeted Drugs for Multiple Myeloma market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Drugs for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Targeted Drugs for Multiple Myeloma Market Report

Report Metric Details
Report Name Targeted Drugs for Multiple Myeloma Market
CAGR 5%
Segment by Type
  • Immunomodulator
  • Proteasome Inhibitors
  • Histone Deacetylase Inhibitors (HDACI)
  • Monoclonal Antibody
  • Others
Segment by Application
  • Hospital
  • Drug Center
  • Clinic
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, J&J, Takeda, Amgen, Bristol Myers Squibb, Abbvie, Seattle Genetics, Karyopharm Therapeutics, PDL BioPharma, Roche, Sumitomo, Merck, Biogen, Schering-Plough, Glaxo, Chiron
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Targeted Drugs for Multiple Myeloma company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Targeted Drugs for Multiple Myeloma Market report?

Ans: The main players in the Targeted Drugs for Multiple Myeloma Market are Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, J&J, Takeda, Amgen, Bristol Myers Squibb, Abbvie, Seattle Genetics, Karyopharm Therapeutics, PDL BioPharma, Roche, Sumitomo, Merck, Biogen, Schering-Plough, Glaxo, Chiron

What are the Application segmentation covered in the Targeted Drugs for Multiple Myeloma Market report?

Ans: The Applications covered in the Targeted Drugs for Multiple Myeloma Market report are Hospital, Drug Center, Clinic, Others

What are the Type segmentation covered in the Targeted Drugs for Multiple Myeloma Market report?

Ans: The Types covered in the Targeted Drugs for Multiple Myeloma Market report are Immunomodulator, Proteasome Inhibitors, Histone Deacetylase Inhibitors (HDACI), Monoclonal Antibody, Others

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Immunomodulator
1.2.3 Proteasome Inhibitors
1.2.4 Histone Deacetylase Inhibitors (HDACI)
1.2.5 Monoclonal Antibody
1.2.6 Others
1.3 Market by Application
1.3.1 Global Targeted Drugs for Multiple Myeloma Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drugs for Multiple Myeloma Market Perspective (2020-2031)
2.2 Global Targeted Drugs for Multiple Myeloma Growth Trends by Region
2.2.1 Global Targeted Drugs for Multiple Myeloma Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Targeted Drugs for Multiple Myeloma Historic Market Size by Region (2020-2025)
2.2.3 Targeted Drugs for Multiple Myeloma Forecasted Market Size by Region (2026-2031)
2.3 Targeted Drugs for Multiple Myeloma Market Dynamics
2.3.1 Targeted Drugs for Multiple Myeloma Industry Trends
2.3.2 Targeted Drugs for Multiple Myeloma Market Drivers
2.3.3 Targeted Drugs for Multiple Myeloma Market Challenges
2.3.4 Targeted Drugs for Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue
3.1.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue (2020-2025)
3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2020-2025)
3.2 Global Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Targeted Drugs for Multiple Myeloma Revenue
3.4 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio
3.4.1 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Multiple Myeloma Revenue in 2024
3.5 Global Key Players of Targeted Drugs for Multiple Myeloma Head office and Area Served
3.6 Global Key Players of Targeted Drugs for Multiple Myeloma, Product and Application
3.7 Global Key Players of Targeted Drugs for Multiple Myeloma, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for Multiple Myeloma Breakdown Data by Type
4.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2020-2025)
4.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2026-2031)
5 Targeted Drugs for Multiple Myeloma Breakdown Data by Application
5.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Application (2020-2025)
5.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Targeted Drugs for Multiple Myeloma Market Size (2020-2031)
6.2 North America Targeted Drugs for Multiple Myeloma Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025)
6.4 North America Targeted Drugs for Multiple Myeloma Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drugs for Multiple Myeloma Market Size (2020-2031)
7.2 Europe Targeted Drugs for Multiple Myeloma Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025)
7.4 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size (2020-2031)
8.2 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025)
8.4 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drugs for Multiple Myeloma Market Size (2020-2031)
9.2 Latin America Targeted Drugs for Multiple Myeloma Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025)
9.4 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size (2020-2031)
10.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025)
10.4 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Details
11.1.2 Celgene Business Overview
11.1.3 Celgene Targeted Drugs for Multiple Myeloma Introduction
11.1.4 Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.1.5 Celgene Recent Development
11.2 Exova
11.2.1 Exova Company Details
11.2.2 Exova Business Overview
11.2.3 Exova Targeted Drugs for Multiple Myeloma Introduction
11.2.4 Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.2.5 Exova Recent Development
11.3 Natco Pharma
11.3.1 Natco Pharma Company Details
11.3.2 Natco Pharma Business Overview
11.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Introduction
11.3.4 Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.3.5 Natco Pharma Recent Development
11.4 Intas Pharmaceuticals
11.4.1 Intas Pharmaceuticals Company Details
11.4.2 Intas Pharmaceuticals Business Overview
11.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
11.4.4 Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.4.5 Intas Pharmaceuticals Recent Development
11.5 Indiabulls Pharmaceutical
11.5.1 Indiabulls Pharmaceutical Company Details
11.5.2 Indiabulls Pharmaceutical Business Overview
11.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
11.5.4 Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.5.5 Indiabulls Pharmaceutical Recent Development
11.6 Cipla
11.6.1 Cipla Company Details
11.6.2 Cipla Business Overview
11.6.3 Cipla Targeted Drugs for Multiple Myeloma Introduction
11.6.4 Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.6.5 Cipla Recent Development
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Details
11.7.2 Glenmark Pharmaceuticals Business Overview
11.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
11.7.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.7.5 Glenmark Pharmaceuticals Recent Development
11.8 Dr Reddy's Laboratories
11.8.1 Dr Reddy's Laboratories Company Details
11.8.2 Dr Reddy's Laboratories Business Overview
11.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Introduction
11.8.4 Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.8.5 Dr Reddy's Laboratories Recent Development
11.9 Qilu Pharmaceutical
11.9.1 Qilu Pharmaceutical Company Details
11.9.2 Qilu Pharmaceutical Business Overview
11.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
11.9.4 Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.9.5 Qilu Pharmaceutical Recent Development
11.10 Chia Tai-Tianqing
11.10.1 Chia Tai-Tianqing Company Details
11.10.2 Chia Tai-Tianqing Business Overview
11.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Introduction
11.10.4 Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.10.5 Chia Tai-Tianqing Recent Development
11.11 Hanson Pharm
11.11.1 Hanson Pharm Company Details
11.11.2 Hanson Pharm Business Overview
11.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Introduction
11.11.4 Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.11.5 Hanson Pharm Recent Development
11.12 Meidakang Huakang Pharmaceutical
11.12.1 Meidakang Huakang Pharmaceutical Company Details
11.12.2 Meidakang Huakang Pharmaceutical Business Overview
11.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
11.12.4 Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.12.5 Meidakang Huakang Pharmaceutical Recent Development
11.13 Shandong Kongfu Pharmaceutical
11.13.1 Shandong Kongfu Pharmaceutical Company Details
11.13.2 Shandong Kongfu Pharmaceutical Business Overview
11.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
11.13.4 Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.13.5 Shandong Kongfu Pharmaceutical Recent Development
11.14 J&J
11.14.1 J&J Company Details
11.14.2 J&J Business Overview
11.14.3 J&J Targeted Drugs for Multiple Myeloma Introduction
11.14.4 J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.14.5 J&J Recent Development
11.15 Takeda
11.15.1 Takeda Company Details
11.15.2 Takeda Business Overview
11.15.3 Takeda Targeted Drugs for Multiple Myeloma Introduction
11.15.4 Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.15.5 Takeda Recent Development
11.16 Amgen
11.16.1 Amgen Company Details
11.16.2 Amgen Business Overview
11.16.3 Amgen Targeted Drugs for Multiple Myeloma Introduction
11.16.4 Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.16.5 Amgen Recent Development
11.17 Bristol Myers Squibb
11.17.1 Bristol Myers Squibb Company Details
11.17.2 Bristol Myers Squibb Business Overview
11.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Introduction
11.17.4 Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.17.5 Bristol Myers Squibb Recent Development
11.18 Abbvie
11.18.1 Abbvie Company Details
11.18.2 Abbvie Business Overview
11.18.3 Abbvie Targeted Drugs for Multiple Myeloma Introduction
11.18.4 Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.18.5 Abbvie Recent Development
11.19 Seattle Genetics
11.19.1 Seattle Genetics Company Details
11.19.2 Seattle Genetics Business Overview
11.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Introduction
11.19.4 Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.19.5 Seattle Genetics Recent Development
11.20 Karyopharm Therapeutics
11.20.1 Karyopharm Therapeutics Company Details
11.20.2 Karyopharm Therapeutics Business Overview
11.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Introduction
11.20.4 Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.20.5 Karyopharm Therapeutics Recent Development
11.21 PDL BioPharma
11.21.1 PDL BioPharma Company Details
11.21.2 PDL BioPharma Business Overview
11.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Introduction
11.21.4 PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.21.5 PDL BioPharma Recent Development
11.22 Roche
11.22.1 Roche Company Details
11.22.2 Roche Business Overview
11.22.3 Roche Targeted Drugs for Multiple Myeloma Introduction
11.22.4 Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.22.5 Roche Recent Development
11.23 Sumitomo
11.23.1 Sumitomo Company Details
11.23.2 Sumitomo Business Overview
11.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Introduction
11.23.4 Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.23.5 Sumitomo Recent Development
11.24 Merck
11.24.1 Merck Company Details
11.24.2 Merck Business Overview
11.24.3 Merck Targeted Drugs for Multiple Myeloma Introduction
11.24.4 Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.24.5 Merck Recent Development
11.25 Biogen
11.25.1 Biogen Company Details
11.25.2 Biogen Business Overview
11.25.3 Biogen Targeted Drugs for Multiple Myeloma Introduction
11.25.4 Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.25.5 Biogen Recent Development
11.26 Schering-Plough
11.26.1 Schering-Plough Company Details
11.26.2 Schering-Plough Business Overview
11.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Introduction
11.26.4 Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.26.5 Schering-Plough Recent Development
11.27 Glaxo
11.27.1 Glaxo Company Details
11.27.2 Glaxo Business Overview
11.27.3 Glaxo Targeted Drugs for Multiple Myeloma Introduction
11.27.4 Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.27.5 Glaxo Recent Development
11.28 Chiron
11.28.1 Chiron Company Details
11.28.2 Chiron Business Overview
11.28.3 Chiron Targeted Drugs for Multiple Myeloma Introduction
11.28.4 Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025)
11.28.5 Chiron Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Celgene
Exova
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla Ltd
Glenmark Pharmaceuticals
Dr. Reddy’s Laboratories
Qilu Pharmaceutical
Chia Tai Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J & J
Takeda
Amgen Inc
Bristol–Myers Squibb
AbbVie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering Plough
Glaxo
Chiron
J & J
List of Tables
 Table 1. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Immunomodulator
 Table 3. Key Players of Proteasome Inhibitors
 Table 4. Key Players of Histone Deacetylase Inhibitors (HDACI)
 Table 5. Key Players of Monoclonal Antibody
 Table 6. Key Players of Others
 Table 7. Global Targeted Drugs for Multiple Myeloma Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Targeted Drugs for Multiple Myeloma Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Targeted Drugs for Multiple Myeloma Market Share by Region (2020-2025)
 Table 11. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Targeted Drugs for Multiple Myeloma Market Share by Region (2026-2031)
 Table 13. Targeted Drugs for Multiple Myeloma Market Trends
 Table 14. Targeted Drugs for Multiple Myeloma Market Drivers
 Table 15. Targeted Drugs for Multiple Myeloma Market Challenges
 Table 16. Targeted Drugs for Multiple Myeloma Market Restraints
 Table 17. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Targeted Drugs for Multiple Myeloma Market Share by Players (2020-2025)
 Table 19. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2024)
 Table 20. Ranking of Global Top Targeted Drugs for Multiple Myeloma Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Targeted Drugs for Multiple Myeloma Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Targeted Drugs for Multiple Myeloma, Headquarters and Area Served
 Table 23. Global Key Players of Targeted Drugs for Multiple Myeloma, Product and Application
 Table 24. Global Key Players of Targeted Drugs for Multiple Myeloma, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2020-2025)
 Table 28. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2026-2031)
 Table 30. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2020-2025)
 Table 32. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2026-2031)
 Table 34. North America Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Targeted Drugs for Multiple Myeloma Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Celgene Company Details
 Table 50. Celgene Business Overview
 Table 51. Celgene Targeted Drugs for Multiple Myeloma Product
 Table 52. Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 53. Celgene Recent Development
 Table 54. Exova Company Details
 Table 55. Exova Business Overview
 Table 56. Exova Targeted Drugs for Multiple Myeloma Product
 Table 57. Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 58. Exova Recent Development
 Table 59. Natco Pharma Company Details
 Table 60. Natco Pharma Business Overview
 Table 61. Natco Pharma Targeted Drugs for Multiple Myeloma Product
 Table 62. Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 63. Natco Pharma Recent Development
 Table 64. Intas Pharmaceuticals Company Details
 Table 65. Intas Pharmaceuticals Business Overview
 Table 66. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product
 Table 67. Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 68. Intas Pharmaceuticals Recent Development
 Table 69. Indiabulls Pharmaceutical Company Details
 Table 70. Indiabulls Pharmaceutical Business Overview
 Table 71. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product
 Table 72. Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 73. Indiabulls Pharmaceutical Recent Development
 Table 74. Cipla Company Details
 Table 75. Cipla Business Overview
 Table 76. Cipla Targeted Drugs for Multiple Myeloma Product
 Table 77. Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 78. Cipla Recent Development
 Table 79. Glenmark Pharmaceuticals Company Details
 Table 80. Glenmark Pharmaceuticals Business Overview
 Table 81. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product
 Table 82. Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 83. Glenmark Pharmaceuticals Recent Development
 Table 84. Dr Reddy's Laboratories Company Details
 Table 85. Dr Reddy's Laboratories Business Overview
 Table 86. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product
 Table 87. Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 88. Dr Reddy's Laboratories Recent Development
 Table 89. Qilu Pharmaceutical Company Details
 Table 90. Qilu Pharmaceutical Business Overview
 Table 91. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product
 Table 92. Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 93. Qilu Pharmaceutical Recent Development
 Table 94. Chia Tai-Tianqing Company Details
 Table 95. Chia Tai-Tianqing Business Overview
 Table 96. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product
 Table 97. Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 98. Chia Tai-Tianqing Recent Development
 Table 99. Hanson Pharm Company Details
 Table 100. Hanson Pharm Business Overview
 Table 101. Hanson Pharm Targeted Drugs for Multiple Myeloma Product
 Table 102. Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 103. Hanson Pharm Recent Development
 Table 104. Meidakang Huakang Pharmaceutical Company Details
 Table 105. Meidakang Huakang Pharmaceutical Business Overview
 Table 106. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product
 Table 107. Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 108. Meidakang Huakang Pharmaceutical Recent Development
 Table 109. Shandong Kongfu Pharmaceutical Company Details
 Table 110. Shandong Kongfu Pharmaceutical Business Overview
 Table 111. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product
 Table 112. Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 113. Shandong Kongfu Pharmaceutical Recent Development
 Table 114. J&J Company Details
 Table 115. J&J Business Overview
 Table 116. J&J Targeted Drugs for Multiple Myeloma Product
 Table 117. J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 118. J&J Recent Development
 Table 119. Takeda Company Details
 Table 120. Takeda Business Overview
 Table 121. Takeda Targeted Drugs for Multiple Myeloma Product
 Table 122. Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 123. Takeda Recent Development
 Table 124. Amgen Company Details
 Table 125. Amgen Business Overview
 Table 126. Amgen Targeted Drugs for Multiple Myeloma Product
 Table 127. Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 128. Amgen Recent Development
 Table 129. Bristol Myers Squibb Company Details
 Table 130. Bristol Myers Squibb Business Overview
 Table 131. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product
 Table 132. Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 133. Bristol Myers Squibb Recent Development
 Table 134. Abbvie Company Details
 Table 135. Abbvie Business Overview
 Table 136. Abbvie Targeted Drugs for Multiple Myeloma Product
 Table 137. Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 138. Abbvie Recent Development
 Table 139. Seattle Genetics Company Details
 Table 140. Seattle Genetics Business Overview
 Table 141. Seattle Genetics Targeted Drugs for Multiple Myeloma Product
 Table 142. Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 143. Seattle Genetics Recent Development
 Table 144. Karyopharm Therapeutics Company Details
 Table 145. Karyopharm Therapeutics Business Overview
 Table 146. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product
 Table 147. Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 148. Karyopharm Therapeutics Recent Development
 Table 149. PDL BioPharma Company Details
 Table 150. PDL BioPharma Business Overview
 Table 151. PDL BioPharma Targeted Drugs for Multiple Myeloma Product
 Table 152. PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 153. PDL BioPharma Recent Development
 Table 154. Roche Company Details
 Table 155. Roche Business Overview
 Table 156. Roche Targeted Drugs for Multiple Myeloma Product
 Table 157. Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 158. Roche Recent Development
 Table 159. Sumitomo Company Details
 Table 160. Sumitomo Business Overview
 Table 161. Sumitomo Targeted Drugs for Multiple Myeloma Product
 Table 162. Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 163. Sumitomo Recent Development
 Table 164. Merck Company Details
 Table 165. Merck Business Overview
 Table 166. Merck Targeted Drugs for Multiple Myeloma Product
 Table 167. Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 168. Merck Recent Development
 Table 169. Biogen Company Details
 Table 170. Biogen Business Overview
 Table 171. Biogen Targeted Drugs for Multiple Myeloma Product
 Table 172. Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 173. Biogen Recent Development
 Table 174. Schering-Plough Company Details
 Table 175. Schering-Plough Business Overview
 Table 176. Schering-Plough Targeted Drugs for Multiple Myeloma Product
 Table 177. Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 178. Schering-Plough Recent Development
 Table 179. Glaxo Company Details
 Table 180. Glaxo Business Overview
 Table 181. Glaxo Targeted Drugs for Multiple Myeloma Product
 Table 182. Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 183. Glaxo Recent Development
 Table 184. Chiron Company Details
 Table 185. Chiron Business Overview
 Table 186. Chiron Targeted Drugs for Multiple Myeloma Product
 Table 187. Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2020-2025) & (US$ Million)
 Table 188. Chiron Recent Development
 Table 189. Research Programs/Design for This Report
 Table 190. Key Data Information from Secondary Sources
 Table 191. Key Data Information from Primary Sources
 Table 192. Authors List of This Report


List of Figures
 Figure 1. Targeted Drugs for Multiple Myeloma Picture
 Figure 2. Global Targeted Drugs for Multiple Myeloma Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Targeted Drugs for Multiple Myeloma Market Share by Type: 2024 VS 2031
 Figure 4. Immunomodulator Features
 Figure 5. Proteasome Inhibitors Features
 Figure 6. Histone Deacetylase Inhibitors (HDACI) Features
 Figure 7. Monoclonal Antibody Features
 Figure 8. Others Features
 Figure 9. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2024 VS 2031
 Figure 11. Hospital Case Studies
 Figure 12. Drug Center Case Studies
 Figure 13. Clinic Case Studies
 Figure 14. Others Case Studies
 Figure 15. Targeted Drugs for Multiple Myeloma Report Years Considered
 Figure 16. Global Targeted Drugs for Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 17. Global Targeted Drugs for Multiple Myeloma Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 18. Global Targeted Drugs for Multiple Myeloma Market Share by Region: 2024 VS 2031
 Figure 19. Global Targeted Drugs for Multiple Myeloma Market Share by Players in 2024
 Figure 20. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2024)
 Figure 21. The Top 10 and 5 Players Market Share by Targeted Drugs for Multiple Myeloma Revenue in 2024
 Figure 22. North America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. North America Targeted Drugs for Multiple Myeloma Market Share by Country (2020-2031)
 Figure 24. United States Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Canada Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Europe Targeted Drugs for Multiple Myeloma Market Share by Country (2020-2031)
 Figure 28. Germany Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. France Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. U.K. Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Italy Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Russia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Nordic Countries Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Share by Region (2020-2031)
 Figure 36. China Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Japan Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. South Korea Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. India Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Australia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Latin America Targeted Drugs for Multiple Myeloma Market Share by Country (2020-2031)
 Figure 44. Mexico Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Brazil Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Share by Country (2020-2031)
 Figure 48. Turkey Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. UAE Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Celgene Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 52. Exova Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 53. Natco Pharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 54. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 55. Indiabulls Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 56. Cipla Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 57. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 58. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 59. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 60. Chia Tai-Tianqing Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 61. Hanson Pharm Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 62. Meidakang Huakang Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 63. Shandong Kongfu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 64. J&J Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 65. Takeda Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 66. Amgen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 67. Bristol Myers Squibb Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 68. Abbvie Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 69. Seattle Genetics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 70. Karyopharm Therapeutics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 71. PDL BioPharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 72. Roche Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 73. Sumitomo Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 74. Merck Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 75. Biogen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 76. Schering-Plough Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 77. Glaxo Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 78. Chiron Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2020-2025)
 Figure 79. Bottom-up and Top-down Approaches for This Report
 Figure 80. Data Triangulation
 Figure 81. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Global ImmunOthersapy Drugs for Multiple Myeloma Market Research Report 2024
Global Traditional ChemOthersapy Drugs for Multiple Myeloma Market Research Report 2024
Global Targeted Drugs for Breast Cancer Market Research Report 2024
Hematological Malignancies Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematological Malignancy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Monoclonal Antibody Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hematological Malignancy Treatment Market Research Report 2025
Global Amyloidosis Therapeutics Market Research Report 2024
Global Immune Drugs Market Insights Forecast to 2030
Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024
Prescription Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Kidney Cancer Targeted Therapy Market Research Report 2025
Hematological Malignancies Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Myelodysplastic Syndrome Drug Market Research Report 2025
Global Myelodysplastic Syndrome Treatment Market Research Report 2024
Myeloid Cells Targeting Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Gynecological Cancers Drug Market Research Report 2025
Global Kidney Cancer Diagnosis Market Research Report 2025
Global Diagnostic Guidewire Market Research Report 2024
Global Recurrent Glioblastoma Multiforme Treatment Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions